Description
A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With The Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)
Location: REDI (East Bay)
Please Contact Nhu Tran or call 510.204.3428
Principal Investigator
Co-Investigator(s)
Related Studies
Breast Cancer Chemoprevention in Primary Care at Geisinger
Investigators: External PI, Principal Investigator, Xiaowei (Sherry) Yan, PhD, MS